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Sporotrichosis is a subcutaneous mycosis distributed worldwide and is frequently
reported in countries with tropical climates, as Latin America countries. We previously
demonstrated that mice with sporotrichosis produce specific antibodies against a
70-kDa fungal protein, indicating that specific antibodies against this molecule may
help to control the sporotrichosis. IgG1 monoclonal antibody was generated, and called
mAbP6E7, in mice against a 70-kDa glycoprotein (gp70) of S. schenckii. The mAbP6E7
showed prophylactic and therapeutic activity against sporotrichosis. However, this
antibody has a murine origin, and this can generate an immune response when
administered to humans, precluding its use for a prolonged time. For its possible use
in the treatment of human sporotrichosis, we humanized the mAbP6E7 by genetic
engineering. Once expressed, the humanized antibodies had good stability and were
able to bind to the 70-kDa cell wall antigens of Sporothrix schenckii and S. brasiliensis.
The humanized P6E7 were able to opsonize S. schenckii yeasts, thus increasing
the phagocytic index in human monocyte-derived macrophages. The treatment with
humanized P6E7 decreased fungal burden in vivo. These data suggest that humanized
P6E7 may have a therapeutic role in sporotrichosis.
Keywords: humanized antibody, S. schenckii, sporotrichosis
INTRODUCTION
Sporotrichosis is a subcutaneous mycosis, caused by Sporothrix sp., affecting animals and
humans and frequently involves the lymphatic system. Sporothrix sp. include fungi with thermal
dimorphism, in which the mycelial form, found in soil, is saprophytic, and the yeast form, which is
found in the host tissue, is parasitic (Bonifaz and Vazquez-Gonzalez, 2010; Vasquez-del-Mercado
et al., 2012). Sporotrichosis is distributed worldwide but is frequently reported in countries
with subtropical and tropical climates, as the Latin America countries (Schechtman, 2010). The
traumatic inoculation of the conidia and hyphae of this fungus results in the development of
subcutaneous mycoses. Within the infected tissue, the fungus differentiates into its yeast form and
may spread to other tissues (Barros et al., 2011). The largest epidemic of sporotrichosis because
of zoonotic transmission was described in Rio de Janeiro between 1998 and 2004, in which 759
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humans were diagnosed with sporotrichosis (Barros et al., 2008;
Freitas et al., 2010). Marimon et al. (2007) described four new
species, S. globosa, S. brasiliensis, S. Mexicana, and S. luriei. These
new species have been found to have a worldwide distribution.
However, S. brasiliensis is apparently restricted to Brazil, and
S. mexicana is restricted to Mexico.
The fungus virulence and the host immune responses are
essential for the development and severity of sporotrichosis.
The recent sporotrichosis outbreaks in Rio de Janeiro city,
demonstrates the emergence of feline zoonotic transmission and
the prevalence of S. brasiliensis in the sporotrichosis, creating a
new paradigm of this disease (Lopes-Bezerra and Mora-Montes,
2015).
Different drug protocols are used for the treatment of
sporotrichosis and include terbinafine, potassium iodide,
itraconazole, fluconazole, and the amphotericin B (Song et al.,
2011). Adverse events, as vomiting and diarrhea, nausea,
headache, hypersensitivity reactions, abdominal pain, and liver
dysfunction, can occur (Lopez-Romero et al., 2011).
In a previous study, we demonstrated that sporotrichosis,
caused by Sporothrix schenckii are able to produce specific IgG
antibodies against a 70-kDa fungal protein (gp70), demonstrating
that specific antibodies against the gp70 may help control the
sporotrichosis (Nascimento et al., 2008). To understand the role
of IgG mediated response in sporotrichosis, we produced an
IgG1 monoclonal antibody against gp70 of S. schenckii, called
mAbP6E7. To evaluate the protective effect of the mAbP6E7
in vivo, mice infected with S. schenckii were passively immunized.
A significant reduction in fungal burden in the spleen and liver
of mice treated with mAbP6E7 before and during experimental
sporotrichosis caused by S. schenckii was observed (Nascimento
et al., 2008). Recently, our group showed that mice treated
with P6E7 and infected with a strain isolated from a case of
feline sporotrichosis, strain 5110 (ATCC MYA – 4823) showed
a decreased fungal burden in its organs (de Almeida et al., 2015).
The mAb P6E7 showed prophylactic and therapeutic activity
against sporotrichosis. However, this antibody has a murine
origin, and this can generate an immune response when
administered to humans, precluding its use for a prolonged time.
For its possible use in the treatment of human sporotrichosis, our
proposal was the humanization of the mAb P6E7 through genetic
engineering.
Here we humanized the mAbP6E7 and proved their binding
ability to the fungus and effector function. We also demonstrated
that the treatment with humanized P6E7 decreased the fungal
burden in experimental sporotrichosis. Together, these data
demonstrated the functionality of humanized P6E7 and their
efficiency in the treatment of experimental sporotrichosis.
MATERIALS AND METHODS
Microorganism and Culture Conditions
The strains used were Sporothrix schenckii M-64 (ATCC MYA
4822) and Sporothrix brasiliensis 5110 (ATCC MYA 4823). The
strains were maintained by regular passages on animals and were
grown on Sabouraud dextrose agar at 25◦C for 7 days. The yeast
form was obtained by cultivation in BHI agar at 37◦C for 7 days.
Animals
Female BALB/c mice at 10 weeks of age (weighing approximately
24 g) were obtained from the Animal House Production
and Experimentation Facility of the Faculty of Pharmaceutical
Sciences and Institute of Chemistry of the University of São
Paulo. The mice were maintained in a SPF environment (specific
pathogen free) and housed in temperature controlled rooms at
23–25◦C with free access to food and water throughout the
experiments.
Human Ethics Statement
This study was carried out in accordance with the
recommendations of Ethical Committee of the Faculty of
Pharmacy of the University of São Paulo with written informed
consent from all subjects. All subjects gave written informed
consent in accordance with the Declaration of Helsinki.
Animal Ethics Statement
This study was carried out in accordance with the
recommendations of Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health. The protocol was
approved by the Brazilian Conselho Nacional de Controle da
Experimentação Animal (CONCEA).
Computational Analysis
For computational analysis, a standard protocol was used
(Silva et al., 2009). Briefly, human VH and VL framework
sequences were extracted from the Swiss-Prot or GenBank.
(A sequence search was performed with FASTA (Pearson,
2000) or BLAST (Altschul et al., 1997). ClustalW (Higgins
et al., 1996) was used for multisequence alignment, running
in BioEdit1. Sterically constrained atoms were detected using
similar tri-dimensional models from the Protein Data Bank2.
Model visualization and atom-to-atom distance calculations were
performed in RASMOL version 2.6 (Bernstein, 2000). Variable
region numbering followed Kabat’s convention (Kabat and Wu,
1991).
Construction of Humanized FvFc
Expression Vector
The plasmids were constructed using standard cloning methods
(Sambrook and Russell, 2001). The VH and VL humanized P6E7
fragments were synthesized and confirmed by sequencing. The
scFv (VH-linker-VL) region was cloned into a pMIRES vector
using its XmaI and XhoI restriction sites to generate pHP6E7.
This construction generated a VH-linker-VL fragment fused with
the human IgG1 CH2CH3 domains. The nucleotide sequences
were deposited in the GenBank with the accession numbers:
BankIt1984561 VL KY488459
BankIt1984561 VH KY488460
1http://www.mbio.ncsu.edu/bioedit/bioedit.html
2http://www.pdb.org
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hP6E7 Production and Purification
CHO-K1 cells were routinely cultured in Ham-F2 (HyClone)
supplemented with 10% FBS. Approximately 9 × 106 cells were
seeded in a 15-cm cell culture dish. Cells were transfected
using the jetPEI reagent (Polyplus Transfection) according to
the manufacturer’s protocol and cultured in Ham-F2 with
1.25% ultra-low IgG FBS (Invitrogen). After 72 h, the culture
supernatants were recovered. The supernatant containing the
hP6E7 antibody were purified using a HiTrap Protein A column
(GE Healthcare) equilibrated with 20 mM sodium phosphate at
pH 7.0 and eluted with 0.1 M citric acid at pH 3.5. The eluted
fractions were neutralized with 1 M Tris-HCl at pH 9.0. The
buffer was exchanged using a PD-10 column (GE Healthcare)
equilibrated with PBS. The proteins were concentrated with a
Centriprep-Ultracel YM-10.000 MWCO (Millipore). The protein
concentration was determined by BCA.
Experimental Infection
Two groups of five mice each were inoculated through the
intraperitoneal (i.p.) route with 5 × 106 yeast cells of S. schenckii
M-64 suspended in 0.1 mL of sterile PBS. After 3 days of infection,
the treated groups received 100 µg of hP6E7 in 0.2 mL of sterile
PBS. The control group was inoculated with 0.2 mL of sterile
PBS. After 10 days of infection, the five mice of each group were
euthanized in a CO2 chamber to measure the fungal burden.
The spleen and liver were homogenized, and the supernatants
were collected. The colony forming units (CFU) were assayed by
serial dilution and plating on BHI agar plates. The plates were
incubated up to seven days at 25◦C. The CFU were counted, and
the results are expressed as CFU per g of tissue.
Human Monocyte-Derived Macrophages
Isolation
Human monocyte-derived macrophages isolation was performed
as previously described with a few modifications (Sousa et al.,
2008). Briefly, the peripheral blood of healthy volunteers
was collected in vacuum tubes containing heparin as an
anticoagulant. The separation was performed by centrifugation
for 40 min at 600 g on a density gradient using Ficoll–Hypaque
(Sigma–Aldrich). The cells were aspirated and washed with
sterile PBS. Positive selection using CD14+ magnetic beads
was performed according to the manufacturer’s instructions
(MiltenyiBiotec). The cells were centrifuged, washed and
resuspended in sterile PBS. The monocytes were counted in
a Neubauer chamber (2 × 105) and plated on 24-well plates
containing a round glass coverslip in the bottom in RPMI 1640
(Sigma–Aldrich) containing 10% FBS. The cell culture plates
were incubated for seven days. Cells were left to adhere on culture
plates for 2 days at 37◦C, non-adherent cells were removed and
the medium was exchanged for fresh RPMI 1640 containing
10% FBS.
Phagocytosis Assay and Opsonization
Condition
Prior to infection, S. schenckii M-64 yeast cells were opsonized
with the hP6E7 antibody or not opsonized, as described
previously, with some modifications (Nascimento et al., 2008).
Briefly, 1 × 106 S. schenckii M-64 yeast cells were incubated
with 25 µg of the hP6E7 antibody or without it (control)
in PBS for 1 h at 37◦C under constant agitation. After this
incubation, the yeast cells were washed three times with PBS
to remove the unbound antibodies. Human monocyte-derived
macrophages were infected with the opsonized or non-opsonized
S. schenckii M-64 yeast cells (at a proportion of three yeast cells
to 1 macrophage) for 5 h. The coverslips were stained with
the hematological staining kit InstantProv (NewProv), and the
phagocytic index (PI) was calculated according to the following
formula:
PI =
(
Number of internalized yeast
Number of Monocytes in the same field
)
×100
Immunofluorescence
An immunofluorescence assay was performed as previously
described with a few modifications (Nascimento et al., 2008).
Briefly, S. schenckii M-64 yeast cells from 10-day-old cultures
grown in BHI agar were collected and resuspended in sterile
PBS. The yeast cells (5 × 106) were incubated for 1 h in
sterile PBS containing 0.2% gelatin. The cell suspension was
then incubated for 2 h with 20 µg of hP6E7 diluted in PBS
containing 0.2% gelatin. In the negative control, the yeast cells
were incubated only with sterile PBS. After this period, the
opsonized and non-opsonized yeast cells were washed three
times in sterile PBS and incubated with the anti-human IgG
antibody conjugated with Alexa Fluor 488 (Life Technologies)
(1:200) in sterile PBS containing 0.2% gelatin. All steps were
performed under agitation (37◦C). The yeast cells were washed
with sterile PBS and mounted on glass slides in Gelvatol.
Then, they were examined with a Nikon Microphot FX
microscope.
Western Blot
The hP6E7 antibody was evaluated for its binding capacity
against gp70, which is present in the cell wall of S. schenckii
and S. brasiliensis. The proteins from cell wall were obtained
from yeast cells of S. brasiliensis 5110 and S. schenckii grown
in Erlenmeyer flasks containing 400 mL of YCG medium (yeast
nitrogen–glucose casamino acids) for 7 days with constant
agitation at 9 g at 37◦C. Then, the yeast cells were collected
and incubated with an extraction solution (2 mM DTT, 1 mM
PMSF, and 5 mM EDTA in 25 mM Tris/HCl at pH 8.5) at 4◦C
for 2 h with mild agitation. The supernatant containing the cell
surface proteins was collected and concentrated. Five micrograms
of cell wall proteins was separated by electrophoresis using a
12% SDS polyacrylamide gel, and subsequently, the proteins were
electrotransferred to Hybond ECL nitrocellulose membranes
(GE Healthcare). Finally, the membranes were washed and
developed using the ECL Plus Kit (GE Healthcare).
Statistical Analysis
GraphPad Prism 5 (GraphPad Software) was used for all
statistical analyses. The data were compared using the unpaired
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FIGURE 1 | Construction and purification of hP6E7. (A) Multiple sequence alignment of MabP6E7, human antibody (HA), and humanized heavy chain (hVH) or
humanized light chain (hVL). (B) hP6E7 was run under reducing condition in SDS-PAGE and stained with silver stain. Lane 1: Unstained protein molecular weight
marker. Black arrows indicates 70 and 50 kDa. Lane 2: Purified hP6E7. (C) Schematic representation of a FvFc molecule. FvFcs are immunoglobulin-like structures
comprising a homodimeric pair of VH and VL, joined with a flexible linker, a hinge, CH2, and CH3 domains. The nucleotide sequences were deposited in the
GenBank with the accession numbers: BankIt1984561 VL KY488459 and BankIt1984561 VH KY488460.
t-test. Differences were considered statistically significant at
∗p< 0.05; ∗∗p< 0.01; and ∗∗∗p< 0.001.
RESULTS
Construction of the Humanized P6E7
Antibody as a scFc Molecule
Humanized antibodies are human-like antibodies in which only
the complementarity determining regions (CDRs) are murine.
This approach can be used to reduce the biggest issue with
non-human antibody (HA) therapy, antibody immunogenicity
(Clark, 2000). Therefore, to generate an effective antibody against
the emerging mycosis sporotrichosis, the murine monoclonal
antibody P6E7 was humanized. The P6E7 humanization was
performed as described previously (Caldas et al., 2003). To reduce
the mouse antibody immunogenicity, the VH and VL sequences
of mAbP6E7 were compared to a HA database (GenBank,
EMBL, PDB) to generate a similar human-like IgG polypeptide
sequence.
These sequences were used as a framework for mAbP6E7
CDRs. Structural analyzes using the BioEdit Sequence Alignment
Editor program were carried out to identify structural
impediments in the human protein. The hP6E7 VH and
VL were designed as scFc fragments (a single-chain Fv fused to
a human IgG1 Fc) (Figure 1C) in the mammalian expression
vector pMIRES. The sequences of heavy and light chain hP6E7
and MabP6E7 are similar (Figure 1A). The humanized antibody
was expressed in the CHO-K1 cell line, and clones expressing the
antibodies were obtained by positive selection. The humanized
antibody was purified by affinity chromatography from cell
culture supernatants. As expected, the hP6E7 preparation
under reducing conditions is a 55-kDa homodimeric protein
(Figure 1B), similar to other humanized scFc molecules (Silva
et al., 2009).
hP6E7 Recognizes the gp70 Protein
Our group characterized a 70-kDa antigen (gp70) in the
exoantigen of S. schenckii and S. brasiliensis using mAbP6E7
(Nascimento et al., 2008; de Almeida et al., 2015). mAbP6E7
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FIGURE 2 | hP6E7 binds to Sporothrix sp. antigens. Western blot analysis
of the cell wall extracts of Sporothrix schenckii (A) or S. brasiliensis (B).
Membrane was incubated with hP6E7 or mAbP6E7.
recognizes the gp70 protein from S. schenckii and S. brasiliensis
in the exoantigen preparation of these strains (Castro et al.,
2013). To evaluate the capacity of hP6E7 to bind to gp70, the
cell wall preparation proteins from S. schenckii and S. brasiliensis
were resolved by SDS-PAGE for the immunodetection of gp70
by hP6E7 in Western blot assays. We showed that hP6E7 and
the mAbP6E7 binds proteins with the same molecular weights
in S. schenckii (Figure 2A) and S. brasiliensis (Figure 2B). In
S. schenckii and S. brasiliensis the molecular weight of the gp70
protein recognized by both antibodies was closer to 70 kDa.
Our group showed that the molecular weight of gp70 may
vary due to glycosylation sites present in gp70 in S. brasiliensis,
while these sites are absent in S. schenckii (Castro et al., 2013).
In conclusion, we suggest that hP6E7 could recognize the gp70
antigen in both Sporothrix sp. species.
hP6E7 Binds to the gp70 Protein on the
Surface of S. schenckii and
S. brasiliensis
The next experiment was to analyze the binding activity of
hP6E7 to gp70 on the surface of fungi. To probe this binding,
we performed an immunofluorescence assay. Yeast cells of
S. schenckii and S. brasiliensis were incubated with hP6E7 and
then labeled with Alexa Fluor 488-conjugated anti-human IgG.
As expected, we observed a strong signal on the surface of
S. schenckii cells (Figure 3A). On the other hand, we observed a
weak but reliable signal on the S. brasiliensis cell wall (Figure 3B).
This weak fluorescence is due to the low amount of gp70 on the
surface of S. brasiliensis, as previously demonstrated (Castro et al.,
2013).
hP6E7 Enhances the Phagocytosis of
S. schenckii by Human Macrophages
As hP6E7 showed binding activity on the surface of fungus, we
evaluated if human monocyte-derived macrophages were able
to recognize the Fc human fraction from hP6E7 promoting
yeast phagocytosis. Thus, we analyzed the interaction between
FIGURE 3 | hP6E7 binds to S. schenckii and S. brasiliensis cell wall. (A) S. schenckii and (B) S. brasiliensis cells were incubated for 2 h with or not 20 µg of
hP6E7 diluted in PBS containing 0.2% of gelatin. Both groups, hP6E7 and control, were incubated with anti-human IgG conjugated with Alexa Fluor 488 in sterile
PBS containing 0.2% gelatin, and visualized under a fluorescence microscopy.
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FIGURE 4 | hP6E7 enhances the phagocytosis against S. schenckii by macrophages human cells. (A) Monocyte-derived macrophages human cells were
infected with S. schenckii yeast cells opsonized or not by hP6E7 for 5 h. Yeast internalization was counted by optical microscopy. (B) Phagocytosis index of yeast
cells opsonized with 25 µg of hP6E7 and yeast cells treated with sterile PBS. Data are the means ± SD. ∗∗∗p < 0.001.
S. schenckii and CD14+ human monocyte-derived macrophages.
As expected, human monocyte-derived macrophages were able
to phagocytose the S. schenckii yeast, and opsonized yeast showed
a higher phagocytosis ability compared to non-opsonized yeast
(Figure 4). Our group has already shown that opsonization
by mAbP6E7 was able to increase the phagocytosis index in
murine macrophages in a concentration-dependent manner and
increase NO production (Nascimento et al., 2008). These data
demonstrate that hP6E7 is fully functional and is able to recognize
the Sporothrix sp. antigen, leading to enhanced recognition by
phagocytic cells.
hP6E7 Treatment Decreases the Fungal
Burden In vivo
We evaluated if the humanized antibody against gp70 could
influence sporotrichosis infection (Figure 5). BALB/c mice were
treated with hP6E7 after 3 days of S. schenckii infection and
euthanized after 10 days of infection to evaluate the fungal burden
in the spleen and liver (Figure 5A). Although hP6E7 has a human
Fc fraction, it can be recognized by non-human cells, but with
reduced effectivity. The treatment with hP6E7 decreased the
fungal burden in the spleen after 10 days of infection compared
with the control (Figure 5B).
DISCUSSION
The treatment of sporotrichosis is not always easy, since
the drugs of choice to combat sporotrichosis require long
periods of treatment, and relapses occur, especially in
immunocompromised patients. In some fungal diseases,
such as paracoccidioidomycosis (Buissa-Filho et al., 2008) and
candidiasis (Moragues et al., 2003) the use of mAbs confers
protection. In some case, the use of mAbs modifies the course of
infection as observed in experimental infection by Cryptococcus
neoformans (Rivera et al., 2005). In addition, mAbs against
Cryptococcus neoformans (Larsen et al., 2005) and Candida
albicans (Pachl et al., 2006) have been approved for clinical
evaluation by FDA. In systemic candidiasis, antifungal antibodies
provide novel therapies for use in combination with antifungal
drugs (Matthews and Burnie, 2001).
Our group demonstrated that the mAb against gp70 (P6E7)
significantly decreased infections of S. schenckii and S. brasiliensis
in vivo (Nascimento et al., 2008; de Almeida et al., 2015).
However, the use of the murine monoclonal antibody in clinical
practice could induce the production of anti-murine antibodies
(HAMA) in patients (Chiu et al., 2011). Therefore, we developed
a humanized anti-gp70 antibody as FvFc fragments. The antibody
format was chosen for several advantages, as showed in the
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FIGURE 5 | hP6E7 treatment decreases the fungal burden in vivo. (A) Experimental approach for passive immunization with hP6E7 and fungal burden analysis.
(B) Fungal burden in the spleen and the liver of infected mice after the treatment with hP6E7 or PBS. Data are the means ± SD. ∗p < 0.05.
literature (Holliger and Hudson, 2005). The targeting specificity
of the whole mAb is preserved in this fragment; it is poorly
immunogenic and has an increased biodistribution and blood
clearance properties (Hudson and Souriau, 2003; Holliger and
Hudson, 2005).
The process used to complete the humanization of P6E7
replaced the murine components with the amino acid residues
of human homologues to reduce the possibility of inducing
immunogenicity in patients. Humanized antibodies have been
used with success in alternative treatments for several disorders,
including cancer, transplant rejection, and infectious diseases
(Souriau and Hudson, 2003; Cai et al., 2015; DiGiandomenico
and Sellman, 2015). A major problem after the humanization
of an antibody is preserving the capacity of the antibody to
bind the antigen. After the purification of hP6E7, we tested its
capacity to bind gp70. We observed that the humanized antibody
was able to bind to gp70, as demonstrated by immunoblotting
and immunofluorescent assays. These results indicated that
hP6E7 did not lose its affinity and capacity to bind the
antigen.
An important mechanism in antibody-mediated protection is
the opsonization of the microorganism by the Fc gamma receptor
(FCR) (Alvarez et al., 2008). FCR mediates several macrophage
functions, including phagocytosis, the stimulation of cytokine
secretion, and the triggering of respiratory antibody-dependent
cellular cytotoxicity (Clavel et al., 2008; Richards et al., 2008).
The results obtained with murine P6E7 showed that the yeast
cells with anti-gp70 increased the phagocytic index of murine
macrophages. Our results showed that the FvFc fragments of
human P6E7 have the ability to bind to gp70 and that the yeast
cells of S. schenckii with FvFc increase the phagocytic index
of monocyte-derived macrophages. Next, our group analyzed
the efficiency of hP6E7 to control the disease in vivo. Our
results showed that treatment with hP6E7 decreased the fungal
burden only in the spleen during murine sporotrichosis. Recently,
our group also observed the reduction of the fungal burden
in spleen, but not in liver after the mAbP6E7 treatment in
experimental sporotrichosis by S. schenckii and S. brasiliensis (de
Almeida et al., 2015). As the hP6E7 is a humanized antibody,
the Fc gamma receptor (FCR) of mice phagocytes cells can not
have a full recognition of the humanized antibody, reducing
the antibody efficiency. The spleen is an organ with enough
phagocytes cells as macrophages and dendritic cells, being easier
to recognize and clear the fungal load in this organ. While
in the liver, maybe with more doses the fungal burden could
reduce as well. These data show that hP6E7 is efficient in the
treatment of sporotrichosis, showing similar results as mAbP6E7
in vitro and in vivo. Finally, our data suggest that humanized
P6E7 could have a therapeutic role in sporotrichosis and may
justify further development of the humanized antibody as a
biopharmaceutical that could be used in the treatment of fungal
infection.
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